Case report of systemic treatment with ALK inhibitor crizotinib before surgery showing it may provide the potential to cure the initially inoperable tumor. READ ARTICLE
Frontiers in Oncology DOI:10.3389/fonc.2021.655856
Authors: Xiao-Hong Xie, Ze-Jiang Zhan, Yin-Yin Qin, Ju-Hong Jiang, Wei-Qiang Yin, Rong-Hui Zheng, Shi-Yue Li, Cheng-Zhi Zhou
A 46-year-old man, a nonsmoker, was hospitalized owing to complaints of repeated cough and hemoptysis. Enhanced computed tomography scan revealed a large mass with a diameter of 66 mm located in the left lower lobe. Enlarged mediastinal lymph nodes were also identified with bulky station 7... Herein, we have first reported a clinically successful case involving neoadjuvant alectinib... Collectively, neoadjuvant alectinib may be clinically feasible and a registered real-world study will be set to further assess its clinical implication. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.12.133
Authors: Chao Zhang, Li-Xu Yan, Ben-Yuan Jiang, Yi-Long Wu, Wen-Zhao Zhong
Background: Locally advanced NSCLC is one of the most heterogeneous conditions, with multidimensional treatments involved. Neoadjuvant therapy had been commonly considered an optimal management strategy for patients with operable locally advanced. However, as targeted therapy has been widely applied in advanced NSCLC, neoadjuvant targeted therapy has remained poorly explored in locally advanced disease. Conclusion: Neoadjuvant crizotinib may be feasible and well tolerated in locally advanced disease for complete resection. Crizotinib therapy before surgery may provide thorough elimination of circulating molecular residual disease and not influence the reuse of first-line crizotinib, but ongoing prospective trials are warranted to prove its efficacy in the neoadjuvant setting. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2018.10.161
Authors: Chao Zhang, Shao-lei Li, Qiang Nie, Song Dong, Yang Shao, Xue-ning Yang, Yi-long Wu, Yue Yang, Wen-zhao Zhong
